Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Cash (2016 - 2025)

Historic Change in Cash for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $11.8 million.

  • Agios Pharmaceuticals' Change in Cash fell 9300.35% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.0 million, marking a year-over-year decrease of 18501.72%. This contributed to the annual value of -$12.0 million for FY2024, which is 7657.77% up from last year.
  • Agios Pharmaceuticals' Change in Cash amounted to $11.8 million in Q3 2025, which was down 9300.35% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Cash registered a high of $1.8 billion during Q1 2021, and its lowest value of -$918.9 million during Q2 2021.
  • Moreover, its 5-year median value for Change in Cash was $1.9 million (2025), whereas its average is -$1.8 million.
  • Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Change in Cash was 2147055.87% (2021), while the steepest drop was 97284.89% (2021).
  • Agios Pharmaceuticals' Change in Cash (Quarter) stood at -$197.1 million in 2021, then soared by 108.53% to $16.8 million in 2022, then skyrocketed by 42.01% to $23.9 million in 2023, then plummeted by 843.48% to -$177.5 million in 2024, then soared by 106.67% to $11.8 million in 2025.
  • Its Change in Cash was $11.8 million in Q3 2025, compared to $1.9 million in Q2 2025 and $2.7 million in Q1 2025.